Advertisement

ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder

  • Ryan MarinoEmail author
  • Jeanmarie Perrone
  • Lewis S. Nelson
  • Timothy J. Wiegand
  • Evan S. Schwarz
  • Paul M. Wax
  • Andrew I. Stolbach
Position Statement

The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Clinical Toxicology, the American Academy of Emergency Medicine, and the American College of Emergency Physicians is as follows: To increase access for patients to receive treatment for opioid use disorder in the United States, we strongly recommend removing the waiver (“X-waiver”) requirement for buprenorphine prescribing.

Background

Current US law requires prescribers to obtain a waiver (“X-waiver”) for outpatient prescription of buprenorphine [1]. The ongoing epidemic of opioid overdose deaths in North America represents a major public health crisis, with more than 48,000 Americans estimated to have died from opioid overdose in 2017 alone [2]. Opioid use disorder (OUD) is a chronic medical condition that can be treated with pharmacological therapies. In response to growing evidence, there is consensus within the healthcare community that opioid agonist therapy (OAT) is the best...

Keywords

Buprenorphine Waiver X-waiver Opioid use disorder Opioid agonist therapy 

Notes

Sources of Funding

None.

Compliance with Ethical Standards

Conflict of Interest

None.

Disclaimer

While individual practices may differ, this is the position of the American College of Medical Toxicology at the time written, after a review of the issue and pertinent literature.

References

  1. 1.
    Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2018; Epub ahead of print.Google Scholar
  2. 2.
    Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2018. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm Accessed: May 21, 2019.
  3. 3.
    Mancher M, Leshner AI. Medications for Opioid Use Disorder Save Lives. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder: Washington (DC): National Academies Press (US); 2019 Mar. http://www.nationalacademies.org/hmd/Reports/2019/medications-for-opioid-use-disorder-savelives.aspx. Accessed July 1, 2019.
  4. 4.
    Sordo L, Barrio G, Bravo MJ, Indava BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.CrossRefGoogle Scholar
  5. 5.
    Frank CJ, Kushner SE, Doran DA, Stehr-green J. Mandatory reporting of fatal and nonfatal opioid overdoses in a rural public health department. Am J Public Health. 2018;108:1646–8.CrossRefGoogle Scholar
  6. 6.
    Kresina TF, Lubran R. Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health. 2011;8:4102–17.CrossRefGoogle Scholar
  7. 7.
    Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27:669–76.CrossRefGoogle Scholar
  8. 8.
    Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230–42.CrossRefGoogle Scholar
  9. 9.
    Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–35.CrossRefGoogle Scholar
  10. 10.
    Drug Enforcement Administration Office of Diversion Control Drug & Chemical Evaluation Section: Buprenorphine. https://www.deadiversion.usdoj.gov/drug_chem_info/buprenorphine.pdf. Accessed 1 Feb 2019
  11. 11.
    Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of comparative clinical effectiveness, cost-effectiveness and guidelines [internet]. Ottawa (ON): Canadian agency for Drugs and Technologies in Health; 2016 Sep 2.Google Scholar
  12. 12.
    Lee S, Klein-schwartz W, Welsh C, Doyon S. Medical outcomes associated with nonmedical use of methadone and buprenorphine. J Emerg Med. 2013;45:199–205.CrossRefGoogle Scholar
  13. 13.
    Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2018.Google Scholar
  14. 14.
    Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428–50.CrossRefGoogle Scholar
  15. 15.
    Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10:209–19.CrossRefGoogle Scholar
  16. 16.
    Lowfall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8:315–26.CrossRefGoogle Scholar
  17. 17.
    Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45.CrossRefGoogle Scholar
  18. 18.
    Marteau D, Mcdonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open. 2015;5:e007629.Google Scholar
  19. 19.
    Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis - buprenorphine myths and realities. N Engl J Med. 2018;379:1–4.CrossRefGoogle Scholar
  20. 20.
    Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35:108–12.CrossRefGoogle Scholar
  21. 21.
    Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. Subst Abus. 2018;39:263–5.CrossRefGoogle Scholar
  22. 22.
    Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M, Baston K, et al. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abus Treat. 2018;93:19–25.CrossRefGoogle Scholar
  23. 23.
    Lowenstein M, Kilaru A, Perrone J, Meisel Z, Delgado MK. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. [published online ahead of print February 18 2019]. Am J Emerg Med. 2019.  https://doi.org/10.1016/j.ajem.2019.02.025.

Copyright information

© American College of Medical Toxicology 2019

Authors and Affiliations

  • Ryan Marino
    • 1
    Email author
  • Jeanmarie Perrone
    • 2
  • Lewis S. Nelson
    • 3
  • Timothy J. Wiegand
    • 4
  • Evan S. Schwarz
    • 5
  • Paul M. Wax
    • 6
  • Andrew I. Stolbach
    • 7
  1. 1.Case Western Reserve University School of MedicineClevelandUSA
  2. 2.University of PennsylvaniaPhiladelphiaUSA
  3. 3.Rutgers New Jersey Medical SchoolNewarkUSA
  4. 4.University of Rochester Medical CenterRochesterUSA
  5. 5.Division of Emergency MedicineWashington University School of MedicineSt. LouisUSA
  6. 6.University of Texas SouthwesternDallasUSA
  7. 7.Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations